Nexus to build sterile injectable manufacturing facility in Wisconsin
By Akshay Kedari  Date: 2019-07-12

Nexus to build sterile injectable manufacturing facility in Wisconsin

Nexus Pharmaceuticals, a biopharmaceutical company focused on research & development of critical-need injectable medications, recently revealed plans to invest $250 million to build a sterile injectable manufacturing facility at Pleasant Prairie, in Wisconsin, cite source.

For the record, the company specializes in developing advanced processes to manufacture specialty & generic injectable drugs and will be investing in a facility which will focus on the production & supply of injectable drugs in various therapeutic areas including neurology, anesthesia, cardiovascular and oncology.

Mariam Darsot, Chief Executive Officer of Nexus, was reported to say that this investment is required to drive the growth for the U.S. pharmaceutical manufacturing industry. The firm acknowledges the Wisconsin Economic Development Corp., Kenosha Area Business Alliance, the Milwaukee 7 and the Village of Pleasant Prairie for enabling the firm develop plans for this major expansion project, Darsot added.

With an estimated investment of $250 million, the multi-phase project is expected to be completed in 10 years. Construction is planned to commence in August 2019 & is expected to be completed by 2021. After the facility & manufacturing procedures receive approval from the FDA, commercial production is slated to commence in 2022.

As per sources close to the matter, the initial phase investment of $85 million will support a new, 3-story manufacturing facility with ground-breaking technology including an advanced isolator system that can facilitate maximum product protection & sterility, for reducing the risk of contamination. The new facility will also include multiple freeze-drying (lyophilization) machines to support production of the firm’s present portfolio & robust pipeline of generic & specialty injectable drugs.

Reportedly, the new 100,000 sq. ft. facility is being designed by IPS (Integrated Project Services) with Turner Construction providing construction management services. Both companies have strong backgrounds in design & construction of pharmaceutical manufacturing. The facility is expected to provide for the Wisconsin economy as it is anticipated to create more than 77 new jobs in fields of high technology manufacturing & science by 2022.

Source credits: https://finance.yahoo.com/news/nexus-pharmaceuticals-build-industry-leading-203000066.html

About Author

Akshay Kedari    

Akshay Kedari

A qualified computer engineering graduate, Akshay Kedari takes pride in having his way with words. Following his passion for content creation, he writes insightful pieces on aeresearch.net and a few other portals. Also endorsed with a short-term experience in web deve...

Read More

More News By Akshay Kedari

Fibonacci Brands acquires Darwin from Harvest Health & Recreation
Fibonacci Brands acquires Darwin from Harvest Health & Recreation
By Akshay Kedari

Fibonacci Brands has recently announced the acquisition of Darwin from Harvest Health & Recreation (HARV.CN) as its foundation brand. Fibonacci is a leading player in the international cannabis industry. According to James George, founder of Fib...

GVN adds EVIT Center and Chumakov as its new Centers of Excellence
GVN adds EVIT Center and Chumakov as its new Centers of Excellence
By Akshay Kedari

The Global Virus Network (GVN), an international coalition of medical virologists, has recently announced the addition of Australian and Russian researchers. GVN is adding the Center for EVIT (Emerging Viruses, Inflammation & Therapeutics) of th...

Wind Point Partners takes over RTIC to expand business portfolio
Wind Point Partners takes over RTIC to expand business portfolio
By Akshay Kedari

American private equity firm, Wind Point Partners has recently signed an acquisition deal with the one of the biggest direct-to-consumer (D2C) eCommerce providers of drinkware, RTIC. Reportedly, RTIC is Wind Point’s third acquisition of a famil...

Novartis reveals positive data from Phase III ORION trials of inclisiran
Novartis reveals positive data from Phase III ORION trials of inclisiran
By Akshay Kedari

Swiss multinational pharmaceutical firm, Novartis has recently announced results from its Phase III ORION-10 and -11 studies that focus on assessing the individual responses of patients on lowering low-density lipoprotein cholesterol (LDL-C) with inc...

Medtronic to acquire Companion Medical to expand diabetes business
Medtronic to acquire Companion Medical to expand diabetes business
By Akshay Kedari

Medtronic plc, the global leader in medical technologies, has reportedly announced that it is planning to acquire insulin pen manufacturer Companion Medical. The acquisition gives Medtronic access to Companion Medical’s ‘InPen’, wh...